10times
09 - 11 Mar 2021Ended

Gene Therapy for Blood Disorders

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Mar 2021

Frequency

Not Available
Claim event to edit details

As more and more promising results emerge from various clinical 3 trials, it’s essential that this industry comes together to share knowledge, .. Read more optimize trial design and discuss strategies for commercial launch. The 2nd Gene Therapy for Blood Disorders is the only industry meeting specifically dedicated to overcoming the clinical and commercial challenges faced in gene therapy drug development for hemophilia, sickle cell disease, beta thalassemia and other blood disorders. Join the likes of UniQure, Graphite Bio, bluebird bio, Sanofi, Spark Therapeutics and more industry pioneers as they share their latest insights and lessons learned to help accelerate programs to market. Principal investigator for the BioMarin valoctocogene roxaparvovec program John Pasi (Professor, Barts and the London School of Medicine & Dentistry) will be sharing his insights from this experience. Consider the specific long terms risks of gene therapies for blood disorders & discuss current FDA and EMA guidelines with Paul Monahan, Hemophilia Clinical Development Lead, Hematology, Spark Therapeutics.

1   Different Located Editions
Boston, USA03 - 05 Mar 2020
1 Followers
  • Share your Experience
  • Organizer
Logo Follow Company

Hanson Wade Limited

UK362 Total Events / 40 Upcoming Events99+ Followers

More Events From The Organizer